Ascletis Pharma Inc.
Ascletis Pharma Inc. (ASCLF) Financial Performance & Income Statement Overview
Analyze Ascletis Pharma Inc. (ASCLF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Ascletis Pharma Inc. (ASCLF) Income Statement & Financial Overview
View the income breakdown for Ascletis Pharma Inc. ASCLF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $641500.00 | $641500.00 | $0.00 | $0.00 |
| Cost of Revenue | $274000.00 | $274000.00 | $0.00 | $0.00 |
| Gross Profit | $367500.00 | $367500.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.57 | $0.57 | $0.00 | $0.00 |
| R&D Expenses | $85.006M | $85.006M | $66.19M | $66.19M |
| SG&A Expenses | $30.19M | $30.19M | $20.68M | $20.68M |
| Operating Expenses | $115.20M | $115.20M | $86.87M | $86.87M |
| Total Costs & Expenses | $115.47M | $115.47M | $86.87M | $86.87M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.51M | $4.01M | $4.01M | $4.01M |
| EBITDA | -$111.83M | -$111.34M | -$82.96M | -$82.96M |
| EBITDA Ratio | -$174.33 | -$173.55 | $0.00 | $0.00 |
| Operating Income | -$114.83M | -$114.83M | -$86.87M | -$86.87M |
| Operating Income Ratio | -$179.006 | -$179.006 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $29.52M | $29.52M | $21.71M | $21.71M |
| Income Before Tax | -$85.31M | -$85.31M | -$65.16M | -$65.16M |
| Income Before Tax Ratio | -$132.98 | -$132.98 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$99500.00 |
| Net Income | -$85.31M | -$85.31M | -$65.16M | -$65.16M |
| Net Income Ratio | -$132.98 | -$132.98 | $0.00 | $0.00 |
| EPS | -$0.09 | -$0.09 | -$0.06 | -$0.06 |
| Diluted EPS | -$0.09 | -$0.09 | -$0.06 | -$0.06 |
| Weighted Avg Shares Outstanding | $986.77M | $986.77M | $1.02B | $1.02B |
| Weighted Avg Shares Outstanding (Diluted) | $986.77M | $986.77M | $1.02B | $1.02B |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q1 2024 to $641500.00 in Q4 2024. Gross profit remained healthy with margins at 57% in Q4 2024 compared to N/A in Q1 2024. Operating income hit -$114.83M last quarter, sustaining a consistent -17901% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$111.83M. Net income rose to -$85.31M, while earnings per share reached -$0.09. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan